therapeut
effect
pegyl
interferon
pegifn
combin
ribavirin
rbv
chronic
hepat
c
egyptian
patient
low
effort
requir
optim
therapi
achiev
higher
rate
virolog
respons
studi
aim
evalu
safeti
efficaci
hydroxychloroquin
hcq
combin
pegyl
interferon
plu
ribavirin
earli
virolog
respons
evr
chronic
hepat
c
egyptian
patient
egyptian
patient
chronic
hepat
c
viru
infect
divid
two
group
group
administ
standard
care
therapi
pegyl
interferon
plu
ribavirin
week
n
group
administ
hydroxychloroquin
plu
standard
care
therapi
week
n
therapeut
includ
hydroxychloroquin
mg
oral
twice
daili
peginterferon
mg
subcutan
weekli
oral
weightbas
ribavirin
mgday
baselin
characterist
similar
two
group
percentag
earli
virolog
respons
significantli
patient
given
tripl
therapi
patient
given
standard
care
vs
p
respect
biochem
respons
week
also
significantli
higher
patient
given
tripl
therapi
compar
standard
care
vs
p
respect
along
studi
observ
advers
event
mild
similar
across
treatment
group
addit
hydroxychloroquin
pegyl
interferon
plu
ribavirin
improv
rate
earli
virolog
biochem
respons
chronic
hepat
c
egyptian
patient
without
increas
advers
event
therapeut
effect
pegyl
interferon
pegifn
combin
ribavirin
rbv
chronic
hepat
c
egyptian
patient
low
effort
requir
optim
therapi
achiev
higher
rate
virolog
respons
studi
aim
evalu
safeti
efficaci
hydroxychloroquin
hcq
combin
pegyl
interferon
plu
ribavirin
earli
virolog
respons
evr
chronic
hepat
c
egyptian
patient
egyptian
patient
chronic
hepat
c
viru
infect
divid
two
group
group
administ
standard
care
therapi
pegyl
interferon
plu
ribavirin
week
n
group
administ
hydroxychloroquin
plu
standard
care
therapi
week
n
therapeut
includ
hydroxychloroquin
mg
oral
twice
daili
peginterferon
mg
subcutan
weekli
oral
weightbas
ribavirin
mgday
baselin
characterist
similar
two
group
percentag
earli
virolog
respons
significantli
patient
given
tripl
therapi
patient
given
standard
care
vs
p
respect
biochem
respons
week
also
significantli
higher
patient
given
tripl
therapi
compar
standard
care
vs
p
respect
along
studi
observ
advers
event
mild
similar
across
treatment
group
addit
hydroxychloroquin
pegyl
interferon
plu
ribavirin
improv
rate
earli
virolog
biochem
respons
chronic
hepat
c
egyptian
patient
without
increas
advers
event
j
med
virol
wantuck
et
al
million
infect
individu
world
repres
total
popul
khattab
et
al
hcv
patient
chronic
infect
risk
develop
hcvrelat
complic
hepat
cirrhosi
hepatocellular
carcinoma
hcc
kamal
nasser
preval
chronic
hepat
c
chc
egypt
extrem
high
affect
popul
guerra
et
al
six
major
genotyp
seri
subtyp
hcv
identifi
simmond
et
al
preval
hcv
genotyp
egyptian
patient
ray
et
al
hcv
genotyp
one
import
predictor
respons
hcv
standard
therapi
schaefer
et
al
pegyl
interferonalfa
plu
ribavirin
combin
standard
care
therapi
hcv
infect
mann
et
al
rate
sustain
virolog
respons
svr
achiev
result
dual
therapi
dt
hcv
genotyp
hcv
genotyp
muir
et
al
standard
durat
pegifn
rbv
therapi
week
except
slow
respond
detect
hcv
rna
week
undetect
hcv
rna
week
treatment
increas
dual
therapi
durat
week
may
obtain
higher
rate
svr
pearlman
et
al
new
oral
compound
known
directli
act
antivir
agent
daa
introduc
treatment
chronic
hcv
infect
svr
rate
explain
might
soon
abil
cure
patient
hcv
relaps
patient
previou
dual
therapi
resist
patient
kowdley
et
al
sinc
telaprevir
boceprevir
approv
first
gener
proteas
inhibitor
new
standard
line
therapi
genotyp
hcv
patient
addit
standard
classic
therapi
relaps
previou
nonrespond
dual
therapi
shown
low
svr
rate
new
therapi
addit
observ
mani
side
effect
especi
patient
advanc
grade
hepat
fibrosi
aghemo
et
al
sinc
fda
approv
sofosbuvir
sof
simeprevir
sim
daclatasvir
dcv
new
gener
daa
higher
svr
rate
fewer
side
effect
shorter
durat
treatment
abdelrazek
wake
previous
mention
daa
use
combin
without
pegifn
andor
rbv
combin
differ
durat
therapi
base
use
combin
optim
regimen
ifn
elig
patient
combin
pegifn
rbv
plu
sof
sim
dcv
week
ifn
inelig
patient
best
treatment
cours
combin
sofrbv
week
combin
sofsim
sofdcv
without
rbv
week
moham
et
al
hcv
exist
heterogen
pool
genet
variant
within
infect
patient
treatment
expand
use
daa
near
futur
anticip
part
patient
develop
resist
fail
achiev
svr
ahm
felmle
need
develop
antihcv
agent
efficaci
cost
effect
lower
resist
minim
advers
effect
hydroxychloroquin
hcq
known
sinc
report
use
antimalari
agent
oneil
et
al
hydroxychloroquin
found
immunomodulatori
properti
enabl
use
treatment
autoimmun
diseas
rheumatoid
arthriti
wozniacka
et
al
addit
antimalari
effect
immunosuppress
activ
hcq
shown
biochem
charact
render
activ
viral
infect
savarino
et
al
found
hcq
exert
direct
antivir
effect
sever
virus
includ
member
flavivirus
retrovirus
coronavirus
inhibit
phdepend
step
replic
insid
host
cell
savarino
et
al
moreov
report
hcq
antivir
action
human
pathogen
virus
includ
hepat
b
c
virus
chandramohan
et
al
hydroxychloroquin
found
block
entir
replic
cycl
hepat
viru
inhibit
uncoat
step
insid
hepatocyt
bishop
furthermor
suggest
sever
vitro
studi
hcv
replic
use
process
involv
cellular
autophag
proteolysi
inhibit
hcq
meerten
et
al
studi
aim
investig
efficaci
hydroxychloroquin
addon
therapi
togeth
standardofcar
therapi
earli
virolog
respons
chronic
hepat
c
egyptian
patient
studi
conduct
egyptian
patient
chronic
hepat
c
accord
ethic
principl
origin
conform
declar
helsinki
studi
protocol
approv
viral
hepat
treatment
center
ministri
health
egypt
patient
provid
written
inform
consent
particip
studi
patient
consid
elig
enrol
studi
agreeabl
follow
criteria
male
nonpregn
femal
egyptian
patient
chronic
activ
hepat
c
genotyp
age
year
old
neg
hbsag
posit
antihcv
white
blood
cell
count
wbc
neutrophil
count
platelet
mm
hemoglobin
content
hb
gmdl
male
gmdl
femal
serum
creatinin
sc
mgdl
evid
chronic
hepat
establish
liver
biopsi
perform
within
month
commenc
studi
accord
metavir
score
system
exclus
criteria
includ
decompens
liver
diseas
well
caus
liver
diseas
hcv
bodi
mass
index
bmi
kgm
sever
cardiovascular
retin
thyroid
disord
hb
gmdl
absolut
neutrophil
count
anc
platelet
count
liver
biopsi
accord
metavir
score
system
grade
necroinflamm
stage
degre
fibrosi
patient
administ
antivir
immunosuppress
therapi
within
month
prior
therapi
present
work
prospect
random
control
intervent
singleblind
studi
conduct
singl
center
hepat
virus
care
unit
fayoum
gener
hospit
fayoum
governor
egypt
januari
novemb
enrol
patient
divid
two
group
accord
receiv
hcv
therapi
week
group
patient
administ
dual
therapi
pegyl
interferon
plu
ribavirin
rbv
standard
care
week
group
patient
administ
tripl
therapi
hydroxychloroquin
hcq
combin
standard
care
therapi
week
pegyl
interferon
mg
reiferon
retard
vial
rheinminapharm
pharmaceut
compani
cairo
egypt
administ
weekli
subcutan
inject
ribavirin
mg
ribavirin
capsul
minapharm
pharmaceut
compani
cairo
egypt
administ
oral
twice
per
day
food
day
night
ribavirin
dose
adjust
base
patient
bodi
weight
follow
patient
bodi
weight
lower
kg
mg
ribavirin
administ
daili
patient
bodi
weight
higher
kg
mg
ribavirin
administ
daili
hydroxychloroquin
mg
hydroquin
tablet
minapharm
pharmaceut
compani
administ
oral
twice
daili
morn
even
main
efficaci
paramet
earli
virolog
respons
evr
plasma
sampl
collect
determin
plasma
hcvrna
level
baselin
end
studi
week
use
rochecoba
taqman
hepat
c
viru
test
version
lower
limit
quantit
lloq
iuml
evr
defin
undetect
hcv
rna
lloq
week
therapi
refer
complet
evr
log
drop
baselin
hcv
rna
week
therapi
complet
evr
refer
partial
evr
patient
log
drop
hcv
rna
week
refer
nonevr
virolog
failur
biochem
respons
defin
alt
iul
also
evalu
week
earli
biochem
respons
ebr
compar
baselin
level
along
studi
patient
investig
weekli
studi
center
assess
safeti
toler
studi
therapi
monitor
patient
advers
event
ae
vital
sign
physic
examin
clinic
laboratori
measur
advers
event
grade
mild
moder
sever
lifethreaten
accord
us
divis
microbiolog
infecti
diseas
dmid
adult
toxic
tabl
nation
institut
allergi
infecti
diseas
therapeut
dose
reduct
done
sever
laboratori
abnorm
observ
data
statist
analyz
use
spss
statist
packag
social
scienc
program
version
soft
ware
spss
inc
chicago
il
quantit
data
express
mean
ae
standard
deviat
analyz
use
independ
sampl
ttest
qualit
data
express
number
percentag
analyz
use
x
test
multivari
analysi
conduct
identifi
demogrph
diseaserel
characterist
may
affect
evr
use
odd
ratio
confid
interv
ci
signific
level
set
pvalu
enrol
patient
complet
studi
adher
protocol
treatment
discontinu
dropout
observ
sever
advers
event
requir
patient
withdraw
tabl
show
signific
differ
two
studi
group
regard
baselin
characterist
mean
age
patient
year
male
femal
mean
bmi
kgm
regard
baselin
viral
load
patient
within
low
level
within
moder
level
high
baselin
viral
load
also
patient
normal
bright
liver
respect
small
percent
coars
liver
signific
differ
patient
two
group
accord
metavir
necroinflamm
score
fibrosi
score
patient
two
group
statist
differ
tabl
ii
show
extent
virolog
respons
two
studi
group
week
treatment
patient
receiv
tripl
therapi
peginterferon
ribavirin
hydroxychloroquin
experienc
earli
virolog
respons
significantli
experienc
standard
care
group
vs
p
complet
evr
cevr
group
patient
compar
group
patient
significantli
higher
vs
p
respect
partial
evr
pevr
vs
group
respect
also
extent
nonrespons
virolog
failur
significantli
lower
group
compar
group
vs
p
respect
normal
alt
level
patient
administ
hcq
combin
ifn
rbv
highli
significantli
differ
patient
administ
ifn
rbv
alon
tabl
iii
display
earli
biochem
respons
ebr
achiev
patient
group
compar
patient
group
p
data
tabl
iv
show
signific
associ
follow
variabl
age
sex
bmi
baselin
viral
load
baselin
alt
fibrosi
score
evr
either
across
studi
patient
across
patient
group
separ
administr
ifn
rbv
hcq
excel
adher
dropout
welltoler
therapi
ae
lead
discontinu
treatment
tabl
v
frequent
report
ae
mild
similar
group
consist
typic
ifn
rbv
hcqinduc
system
symptom
headach
fatigu
influenzalik
ill
gastrointestin
disturb
sever
life
threaten
ae
report
hematolog
abnorm
notic
except
five
patient
two
suffer
neutropenia
one
patient
group
one
patient
soc
group
suffer
thrombocytopenia
temporari
dose
reduct
peginterferon
one
two
dose
indic
dose
adjust
ribavirin
accord
hemoglobin
level
indic
two
patient
due
declin
hemoglobin
concentr
gdl
minimum
dose
ribavirin
use
reduct
mgday
within
therapeut
rang
notabl
find
relat
vital
sign
systol
diastol
blood
pressur
puls
observ
studi
patient
clinic
signific
ecg
abnorm
also
ocular
ear
abnorm
notic
result
studi
therapi
group
given
pegyl
interferon
plu
ribavirin
group
given
hydroxychloroquin
plu
pegyl
interferon
plu
ribavirin
data
express
mean
ae
sd
number
statist
analysi
data
express
mean
ae
sd
carri
use
unpair
student
ttest
statist
analysi
data
express
number
carri
use
x
test
respons
treatment
chronic
hepat
c
chc
matter
debat
mann
et
al
combin
peginterferon
alfa
ribavirin
cornerston
treatment
standard
care
hcv
genotyp
basi
result
multiplerandom
control
trial
hcv
poor
respons
dual
therapi
pegifnrbv
sustain
virolog
respons
rate
svr
rang
kamal
nasser
past
year
optim
interferon
alfabas
therapi
chc
new
strategi
hcvrelat
medic
studi
increas
svr
rate
zeuzem
last
year
combin
directact
antivir
agent
daa
involv
inhibitor
inhibitor
nucleosid
nonnucleosid
inhibitor
shown
strong
efficaci
achiev
svr
rate
hcv
genotyp
gutierrez
et
al
although
first
gener
daa
increas
rate
svr
administ
combin
pegyl
interferon
mani
sideeffect
remain
approv
nextgener
daa
sofosbuvir
simeprevir
daclatasvir
antivir
therapi
hcv
led
interferonfre
regimen
clinic
applic
douam
et
al
drug
low
barrier
resist
multipl
obstacl
like
appear
futur
use
furthermor
natur
polymorph
certain
hcv
genotyp
subtyp
report
addit
resist
mutat
multipl
daa
alreadi
character
sarrazin
high
cost
medic
especi
lowincom
countri
egypt
high
preval
hcv
urg
grow
need
develop
new
effect
antivir
agent
fewer
side
effect
combin
standard
care
success
hcv
treatment
aim
studi
investig
efficaci
ad
hydroxychloroquin
pegyl
interferon
ribavirin
evr
chronic
hepat
c
egyptian
patient
rational
choos
evr
primari
efficaci
paramet
base
document
predict
valu
evr
toward
chanc
achiev
svr
illustr
patient
without
evr
littl
chanc
achiev
svr
ferenc
et
al
similarli
evr
excel
predictor
treatment
outcom
wherea
absenc
evr
associ
low
chanc
achiev
svr
egyptian
patient
elefsinioti
et
al
present
studi
extent
evr
significantli
patient
receiv
tripl
therapi
peginterferon
ribavirin
hydroxychloroquin
receiv
standard
care
vs
p
also
extent
virolog
failur
significantli
lower
hydroxychloroquin
patient
compar
standard
care
patient
vs
improv
evr
hcqtreat
group
assum
due
report
antivir
activ
hcq
augment
inhibitori
action
standard
care
hepat
c
viral
replic
hepatocyt
antivir
activ
hcq
attribut
fact
hcq
weak
base
greater
tendenc
captur
acid
organel
accumul
insid
result
increas
ph
savarino
et
al
accumul
hcq
within
acid
organel
includ
endosom
lysosom
golgi
vesicl
therebi
increas
ph
main
caus
hcq
antivir
activ
sundelin
terman
explan
hcv
entri
host
cell
phdepend
process
requir
low
ph
perform
conform
chang
essenti
fusion
penetr
uncoat
endocytosi
occur
within
endosom
pathway
ashfaq
et
al
moreov
hcq
might
interfer
posttransl
modif
hcv
envelop
glycoprotein
inhibit
proteas
glycosyltransferas
activ
within
transgolgi
network
endoplasm
vesicl
respons
modif
rolain
et
al
enzym
requir
low
ph
activ
hcq
might
therefor
lead
decreas
viral
infect
impair
envelop
matur
randolph
et
al
base
previou
explan
could
suggest
hcq
increas
evr
suppress
hcv
replic
insid
hepatocyt
shown
pretreat
hepat
cell
hcqinhibit
hepat
c
viru
hcv
entri
clathrinmedi
endocytosi
fusion
within
acid
endosom
compart
blanchard
et
al
moreov
hcq
also
found
activ
hepat
hepat
b
virus
offensperg
et
al
import
notifi
hcq
potenti
inhibit
replic
hepat
virus
also
antivir
activ
virus
low
phdepend
entri
replic
thom
e
et
al
instanc
report
lysosomotrop
activ
hcq
exert
direct
antivir
effect
sever
rna
virus
includ
coronavirus
influenza
viru
flavivirus
human
immunodefici
viru
hiv
savarino
et
al
present
studi
show
hcq
valuabl
effect
alt
normal
patient
receiv
hcq
addit
standard
care
normal
alt
level
week
high
percentag
compar
alt
normal
achiev
patient
receiv
standard
care
alon
obtain
data
accord
report
chronic
activ
hepat
b
viru
patient
treat
hcq
median
month
notic
alt
patient
return
normal
valu
kouroumali
koskina
addit
state
low
dose
chloroquin
cq
analog
hcq
normal
alt
level
patient
chronic
hepat
c
schuppan
et
al
present
work
multivari
analysi
reveal
signific
associ
earli
virolog
respons
studi
patient
age
sex
bmi
baselin
viral
load
baselin
alt
fibrosi
score
either
across
studi
patient
across
patient
group
separ
may
support
evr
achiev
studi
strongli
relat
administ
therapi
alon
without
effect
induc
factor
variabl
find
consist
studi
explain
previous
age
sex
baselin
viral
load
bmi
predict
virolog
respons
shehab
et
al
regard
safeti
toler
studi
therapi
includ
hcq
soc
result
monitor
patient
advers
event
ae
vital
sign
physic
examin
clinic
laboratori
measur
throughout
studi
display
administ
therapi
safe
worsen
abnorm
previous
measur
paramet
induc
soc
therapi
alon
addit
hcq
soc
patient
result
within
normal
rang
half
centuri
long
use
hcq
treatment
rheumatoid
arthriti
malaria
demonstr
safeti
administr
hcq
human
be
michaelid
et
al
likewis
shown
administr
hcq
rheumatoid
arthriti
ra
patient
treatment
cyclosporin
csa
associ
return
mean
level
complet
blood
count
test
urin
analysi
result
liver
enzym
urea
nitrogen
serum
creatinin
normal
signific
increas
level
csa
treatment
kim
et
al
addit
evalu
toxic
effect
hcq
differ
organ
albino
rat
assess
liver
kidney
function
determin
serum
glutam
oxaloacet
transaminas
sgot
serum
glutam
pyruv
transaminas
sgpt
alkalin
phosphatas
alp
total
bilirubin
tb
serum
creatinin
histopatholog
chang
liver
kidney
heart
shown
hcq
safe
welltoler
medic
el
shishtawi
et
al
moreov
assess
safeti
temsirolimu
tem
hcq
test
complet
blood
count
cbc
liver
renal
function
clarifi
combin
standard
dose
tem
highest
dose
hcq
use
clinic
practic
safe
toler
rangwala
et
al
current
studi
frequent
report
advers
event
ae
mild
grade
similar
group
consist
typic
ifn
rbv
hcqinduc
system
symptom
headach
fatigu
influenzalik
ill
gastrointestin
disturb
therapi
well
toler
excel
adher
dropout
ae
lead
discontinu
treatment
observ
safeti
toler
hcq
may
attribut
administ
dose
hcq
durat
use
two
main
factor
affect
frequenc
sever
advers
effect
clinic
abnorm
includ
hepat
renal
hematolog
abnorm
associ
hcq
use
ruizirastorza
et
al
select
dose
hydroxychloroquin
studi
mgday
base
mgkgday
recommend
maximum
safe
dose
longterm
use
ra
patient
evid
retinopathi
main
toxic
effect
associ
longterm
use
hcq
block
furthermor
indic
american
academi
ophthalmolog
cumul
dose
gm
hcq
import
risk
retinopathi
cumul
dose
reach
year
hcq
use
typic
daili
dose
mg
geam
anu
et
al
importantli
select
dose
hcq
also
base
clinic
trial
hcq
achiev
mark
antivir
activ
hiv
infect
potenti
therapeut
outcom
antiretrovir
agent
hcq
use
combin
paton
aboulhab
similarli
report
hcq
welltoler
therapi
clinic
advers
event
associ
use
mild
grade
concern
side
effect
ocular
toxic
thought
occur
adult
dose
remain
less
mgkgday
klinger
et
al
rate
dose
modif
studi
compar
repres
accept
percentag
standard
care
dose
modif
mann
et
al
reassur
safeti
profil
may
support
rational
tri
hcq
higher
dose
longer
durat
futur
trial
limit
present
studi
includ
small
number
patient
compar
larg
number
egyptian
patient
infect
hcv
egyptian
popul
also
perform
studi
singl
center
fayoum
governor
egypt
one
studi
limit
hcv
egyptian
patient
settl
sever
area
egypt
governor
anoth
limit
lack
studi
assess
rapid
virolog
respons
rvr
defin
hcv
rna
neg
week
treatment
although
rvr
strong
predictor
svr
posit
predict
valu
ppv
failur
achiev
evr
strong
predictor
non
svr
neg
predict
valu
npv
independ
patient
pretreat
cost
rvr
assess
high
current
fund
egyptian
ministri
health
depend
assess
evr
suffici
predict
treatment
outcom
studi
end
week
without
continu
administr
hcq
along
ifn
rbv
week
therapi
week
accord
standard
care
protocol
evalu
antivir
activ
hcq
end
treatment
virolog
respons
etr
svr
regard
one
limit
base
consider
studi
first
step
evalu
safeti
efficaci
hcq
svr
hcq
safeti
efficaci
evr
achiev
limit
studi
includ
absenc
doubl
blind
lack
placebo
control
avoid
larger
confirmatori
trial
multicent
studi
larger
number
patient
assess
hcq
effect
combin
standard
care
etr
svr
recommend
addit
hydroxychloroquin
pegyl
interferon
ribavirin
chronic
hepat
c
egyptian
patient
safe
well
toler
significantli
increas
rate
earli
virolog
respons
earli
biochem
respons
